Boston Scientific Corporation vs Nano Dimension Ltd - ADR — how do they compare? Boston Scientific Corporation trades at $51.59 (market cap $74.19B), while Nano Dimension Ltd - ADR trades at $1.65 (market cap $350.49M). The key difference: Boston Scientific Corporation is far larger — about 211.7× Nano Dimension Ltd - ADR's market cap, and Nano Dimension Ltd - ADR is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | NNDM | |
|---|---|---|
Market Cap | $74.19B | $350.49M |
Sector | Health | Technology |
52-Week High | $108.14 | $2.14 |
52-Week Low | $42.63 | $1.21 |
Enterprise Value | $86.27B | -$54.35M |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
NNDM trades at $1.655, up 1.53% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of -$0.03, beating expectations, while revenue grew to $102.44M in 2025. However, net income remains deeply negative at -$293.30M, and cash flow from operations is negative. Recent strategic moves include selling MarkForged to Stratasys and cost-saving initiatives to reduce cash burn.
Outlook: Potential upside from strategic divestitures and cost cuts, but high execution risk and persistent losses pose significant challenges. Investors should weigh the low P/B of 0.73 against sustained profitability concerns and shareholder disputes highlighted in recent news.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →